In contrast, in CML samples carrying a TKI resistant BCR-ABL mutation, SNAI2 expression was even more enhanced than in TKI sensitive samples and helped to drive cell survival in response to TKI (155). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.